Banri Ito, 08 August 2021

In a policy reversal, the US has announced its support for a proposed temporary waiver of intellectual property rights on COVID-19-related pharmaceuticals, although it is unclear how much of the undisclosed information regarding unpatented elements would be disclosed in order to facilitate technology transfer to developing countries. This column argues that most efficient way to achieve equitable vaccine access would be to concentrate production in a smaller number of countries with sufficient production capacity. It also looks at the implications for Japan, which is caught in a dilemma between the need to vaccinate the population quickly and the need to secure incentives for developing domestic vaccine capacity for future pandemics.

Daniel Gros, 18 May 2021

Experience with Covid-19 has shown how vaccinating the population as quickly as possible can be of paramount importance, however with fixed contracts the benefits for early delivery of such vaccines are huge for society, but non-existent for suppliers. Daniel Gros (Centre for European Policy Studies) talks to Tim Philips about why vaccine contracts should have incentives for accelerated production built into them.
The paper discussed can be found here:
Covid Economics Issue 77: Incentives for accelerating the production of Covid-19 vaccines in the presence of adjustment costs by Claudius Gros & Daniel Gros 


Vox eBooks

Vox Talks


CEPR Policy Research